Himalaya Nutravedics India IPO
Upcoming SMEAlready have an account? Apply now
Himalaya Nutravedics India IPO details
Schedule of Himalaya Nutravedics India
| Issue open date | 22 Sep 2026 |
| Issue close date | 24 Sep 2026 |
| UPI mandate deadline | 24 Sep 2026 (5 PM) |
| Allotment finalization | 25 Sep 2026 |
| Refund initiation | 28 Sep 2026 |
| Share credit | 28 Sep 2026 |
| Listing date | 29 Sep 2026 |
| Mandate end date | 09 Oct 2026 |
| Lock-in end date for anchor investors (50%) | 24 Oct 2026 |
| Lock-in end date for anchor investors (remaining) | 23 Dec 2026 |
Note: The schedule is tentative. The anchor lock-in period ends 30 days after the actual allotment date for 50% of the shares and 90 days after for the remaining portion. The allotment status can be checked on the registrar's website and the exchange website.
About Himalaya Nutravedics India
Himalaya Nutravedics manufactures and supplies a range of Ayurvedic and nutraceutical products across multiple dosage forms, including softgel capsules, hardgel capsules, tablets, liquid orals, medicated oils, and protein powders. The company operates through a single integrated manufacturing facility located in Hyderabad, Telangana. Its product portfolio covers therapeutic categories such as pain management, infertility, women’s wellness, gut health, neurological support, and general wellness. The business generates revenue primarily from the sale of Ayurvedic formulations, alongside nutraceutical offerings. The company operates mainly through a business-to-business model, supplying products to stockists, distributors, and third-party contract manufacturing clients across various states in India. It also undertakes custom contract manufacturing for corporate clients under their own brand names utilizing its manufacturing infrastructure. Furthermore, the company is expanding its market presence into direct-to-consumer sales channels through digital platforms, e-commerce marketplaces, and quick commerce delivery services.
Financials of Himalaya Nutravedics India
Issue size
| Funds Raised in the IPO | Amount (₹ crores) |
| Total issue size | 26.50 |
| Fresh Issue – Proceeds go to the company | 26.50 |
Utilisation of proceeds
| Purpose | INR crores (%) |
| Funding Working Capital Requirements | 13.75 (51.89%) |
| Business Development and Digital Marketing Activities | 7.5 (28.30%) |
| General corporate purposes | 5.25 (19.81%) |
Strengths
- Integrated manufacturing facility capable of producing multiple dosage forms.
- Diverse Ayurvedic and nutraceutical product portfolio across key therapeutic areas.
- Established B2B distribution network with presence across 17 Indian states.
- Track record of strong revenue and net profit growth over recent fiscal years.
- In-house quality assurance and control capabilities across production processes.
Risks
- High revenue reliance on Ayurvedic products, accounting for over 90% of sales.
- Significant revenue concentration from top 10 customers representing over 80% of revenue.
- Operations from a single leased manufacturing facility located in Hyderabad, Telangana.
- Pending trademark opposition proceedings for corporate logos and mark applications.
- History of negative cash flows from operating activities due to working capital needs.